Australia's most trusted source of pharma news
Tuesday, 22 October 2019
Lost Your Access?
Labor MP targets PBS record
Motion moved to censure Hunt for 'politicising the PBS'.
J&J loses brand 'halo'
Lawsuits and safety issues take their toll.
Missing MA report appears
Lost KPMG value report surfaces - but not as a report.
PBS listing delays stagnate
Analysis finds no recent fall in listing times.
$200m biotech buy collapses
Melbourne cell therapy maker pulls out of deal.
Generics on the rise in Aust, US
ARTG registrations climb as PBS income falls.
TGA ad code under fire
Consumer rep calls on TGA to toughen up.
CSL moves on alleged theft
Files US lawsuit alleging former exec stole documents.
Aust pharma at 'tipping point'
Commercial Eyes' new recruit talks industry challenges.
TGA moves on Pfizer's Xeljanz
Risk of clots and death for some at higher dose.
Real McCoy moves in at Gilead
Exclusive first chat with new GM Jaime McCoy.
New drugs slump reports TGA
2018-19 hits new low while orphans, extensions climb.
Pharma skills don't pay bills
Talent shortage not impacting pharma wages.
Public clueless on new meds
Large chunk never heard of CAR-T, precision therapies
Vertex strikes PBS deal
December listings for Symdeko, Orkambi.
PBS pressure builds on Hunt
News Corp publishes list of drugs that failed to list.
Generics and OTCs added
Blood pressure and heart options.
Lilly builds migraine franchise
Reyvow new stablemate for Emgality.
Top of the Hill
The challenge of federation
Divide between governments hindering new therapies.
Events & Conferences
© 2003 - 2019 Lush Media
Pharma in Focus
Jolly Good Design